Lessons learnt from a discontinued randomised controlled trial

Williams, Nefyn; Jenkins, Alison; Goulden, Nia; Hoare, Zoe; Hughes, Dyfrig; Wood, Eifiona; Foster, Nadine E; Walsh, David A; Carnes, Dawn; Sparkes, Valerie; Hay, Elaine M; Isaacs, John; Konstantinou, Kika; Morrissey, Dylan; Karppinen, Jaro; Genevay, Stephane; Wilkinson, Clare

Trials

DOI: 10.1186/s13063-018-2801-6

Published: 31/07/2018

Peer reviewed version

Cyswllt i'r cyhoeddiad / Link to publication

Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):

Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Lessons learnt from a discontinued randomised controlled trial: Adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica
(Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC).

Nefyn H Williams  Department of Health Services Research, University of Liverpool, UK

e-mail: nefyn.williams@liverpool.ac.uk  Corresponding author

Alison Jenkins  School of Healthcare Sciences, Bangor University, UK

e-mail: a.jenkins@bangor.ac.uk

Nia Goulden  School of Healthcare Sciences, Bangor University, UK

e-mail: n.goulden@bangor.ac.uk

Zoe Hoare  School of Healthcare Sciences, Bangor University, UK

e-mail: z.hoare@bangor.ac.uk

Dyfrig A Hughes  School of Healthcare Sciences, Bangor University, UK

e-mail: d.a.hughes@bangor.ac.uk

Eifiona Wood  School of Healthcare Sciences, Bangor University, UK

e-mail: e.wood@bangor.ac.uk

Nadine E Foster  Arthritis Research UK Primary Care Centre, Research Institute for Primary Care and Health Sciences, Keele University, UK

e-mail: n.foster@keele.ac.uk
David A Walsh  Arthritis Research UK Pain Centre and National Institute for Health Research Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, UK

e-mail: david.walsh@nottingham.ac.uk

Dawn Carnes  Centre for Primary Care and Public Health, Barts and the London School of Medicine and Dentistry, UK

e-mail: d.carnes@qmul.ac.uk

Valerie Sparkes  School of Healthcare Science, Cardiff University, UK

e-mail: sparkesv@cardiff.ac.uk

Elaine M Hay  Arthritis Research UK Primary Care Centre, Research Institute for Primary Care and Health Sciences, Keele University, UK

e-mail: e.m.hay@keele.ac.uk

John Isaacs  National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, UK

e-mail: john.isaacs@ncl.ac.uk

Kika Konstantinou  Arthritis Research UK Primary Care Centre, Research Institute for Primary Care and Health Sciences, Keele University, UK

e-mail: k.konstantinou@keele.ac.uk
Dylan Morrissey  Centre for Sports and Exercise Medicine, William Harvey Research Institute, Bart's and the London School of Medicine and Dentistry, Queen Mary University of London UK
e-mail: d.morrissey@qmul.ac.uk

Jaro Karppinen  Medical Research Centre Oulu, University of Oulu and Oulu University Hospital, Finland
e-mail: Jaro.Karppinen@ttl.fi

Stephane Genevay  University Hospitals of Geneva, Switzerland
e-mail: Stephane.Genevay@hcuge.ch

Clare Wilkinson  School of Healthcare Sciences, Bangor University, UK
e-mail: c.wilkinson@bangor.ac.uk

Corresponding author:

Professor Nefyn H Williams, Department of Health Services Research, Waterhouse Block B, 1-5 Brownlow Street, Liverpool L69 3GL

Tel: +44 (0)151 795 5305  e-mail: nefyn.williams@liverpool.ac.uk

Word count 3917
Abstract (347 words)

Background: Adalimumab, a biological treatment targeting Tumour Necrosis Factor alpha, might be useful in sciatica. This paper describes the challenges when developing a new treatment pathway for a randomised controlled trial of adalimumab for people with sciatica, and the reasons why the trial was stopped early.

Methods: Pragmatic, parallel group, randomised controlled trial with blinded (masked) participants, clinicians, outcome assessment and statistical analysis in six UK sites.

Participants were identified and recruited from general practices, musculoskeletal services and out-patient physiotherapy clinics. They were adults with persistent symptoms of sciatica of one to six months duration, with moderate to high level of disability. Eligibility was assessed by research physiotherapists according to clinical criteria and participants were randomised to receive two doses of adalimumab (80mg then 40mg two weeks later) or saline placebo sub-cutaneous injections in the posterior lateral thigh. Both groups were referred for a course of physiotherapy.

Outcomes were measured at baseline, six weeks, six months and 12 months' follow-up. The main outcome measure was the disability measured using the Oswestry Disability Index. The planned sample size was 332 with the first 50 in an internal pilot phase.

Results: The internal pilot phase was discontinued after 10 months from opening due to low recruitment (two of the six sites active, eight participants recruited). There were several challenges: contractual delays, one site did not complete contract negotiations and two sites signed contracts shortly before trial closure; site withdrawal due to patient safety concerns; difficulties obtaining excess treatment costs; and in the two sites that did recruit,
recruitment was slower than planned due to operational issues and low uptake by potential participants.

**Conclusion**: Improved patient care requires robust clinical research within contexts in which treatments can realistically be provided. Step changes in treatment, such as the introduction of biologic treatments for severe sciatica, raise complex issues that can delay trial initiation and retard recruitment. Additional preparatory work might be required before testing novel treatments. A randomised controlled trial of TNF alpha blockade is still needed to determine its cost effectiveness in severe sciatica.


**Key words**: feasibility, randomised controlled trial, economic evaluation, sciatica, adalimumab, anti TNF-alpha, biological agents
Background

Sciatica is a well-localised leg pain, attributed to nerve root irritation, that approximates to the dermatomal distribution of the sciatic nerve down the posterior lateral aspect of the leg [1]. It is a common cause of pain and disability [2]. Although most cases resolve, up to 30% might have persistent troublesome symptoms after one year [3,4]. Many patients whose symptoms settle, relapse again later [5]. Typical care pathways in the National Health Service (NHS) involve analgesia prescribed by a general practitioner, referral for physiotherapy [6,7], followed by more invasive treatment such as epidural corticosteroid injection or disc surgery, if symptoms persist [3,4,8]. However, the evidence for most of the non-surgical treatments is weak [9]; new treatment strategies are needed.

Sciatica caused by lumbar nerve root pain usually arises from a prolapsed intervertebral disc [3], which can compress the nerve root [10], but also releases pro-inflammatory factors such as tumour necrosis factor-alpha (TNF-alpha) that may lead to nerve sensitisation [11,12]. Biological agents such as the monoclonal antibody adalimumab bind specifically to TNF-alpha receptors and might have beneficial effects on the inflamed nerve root in sciatica [13]. Two separate network meta-analyses of different treatment strategies for sciatica found that biological agents had the highest probability of having the best outcomes for pain, but with wide confidence intervals [14,15]. A meta-analysis of biological agents for sciatica found insufficient evidence to change practice, but sufficient evidence to suggest that clinically important benefit was possible, and that a definitive RCT was warranted [16].

Sciatica is costly to society [17] and although biological agents are expensive, they may be cost-effective if they reduce the need for more expensive treatments such as disc surgery.
Also as patents expire, cheaper biosimilar drugs are becoming available [18]. Adalimumab is a TNF-alpha blocking antibody that is administered by sub-cutaneous injection, with two doses given two weeks apart and should inhibit TNF-alpha for at least four weeks. Adalimumab dosing for psoriasis or Crohn's disease uses 80mg followed by 40mg subcutaneous injections [19]; the same dosing strategy is proposed in sciatica.

Objective

The aims of the RCT were to evaluate the effectiveness and cost-effectiveness of injections of adalimumab plus physiotherapy compared with placebo injection of 0.9% sodium chloride plus physiotherapy for patients with sciatica who had failed first line primary care treatment. However, the RCT was discontinued because of lack of progress. The aim of this paper is to explore the reasons for this and make recommendations to inform other researchers.

Methods

This was designed as a pragmatic, multi-centre, RCT with blinded (masked) participants, clinicians, outcome assessment and statistical analysis, with concurrent economic evaluation and internal pilot. The Wales Research Ethics Committee (REC) 3 granted approval on 27/05/2015 (15/WA/105), and clinical trial authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) was granted on 15/04/2015 (21996/0002/001-0001). The setting was the NHS in England and Wales, with five collaborating university centres (1-5). We aimed to recruit from six NHS sites overseen by these five centres (A-F). Each collaborating centre would oversee a number of patient
identification centres which consisted of general medical practices, local musculoskeletal services and out-patient physiotherapy clinics. Patients were identified in three ways:

- By their general practitioner (GP)
- Following a search of the general practice patient record database
- After referral to local musculoskeletal services

Patients were invited to participate by letter. Those who were interested were contacted by telephone for pre-screening and if they fitted the inclusion criteria, they were given an appointment in a research clinic run by a research physiotherapist. At this research clinic all potential participants were screened by the research physiotherapist for eligibility. If eligible, participants had blood tests, tuberculosis (TB) screening, biological agents counselling, and magnetic resonance imaging (MRI) to exclude serious spinal pathology. If they were still eligible, at a second screening assessment 2-3 weeks later, informed consent was obtained for trial entry and randomisation (Figure 1).

**Inclusion criteria**

- Clinical features of sciatica
  - Leg pain worse or as bad as back pain
  - Unilateral leg pain approximating a dermatomal distribution
  - Positive neural tension test such as straight leg raise test (SLR) restricted <50 degrees by leg pain, or positive femoral stretch test, or muscle weakness, or loss of tendon reflex, or loss of sensation in a dermatomal distribution
- 18 years of age and older
- Persistent symptoms for at least four weeks and less than six months
- Moderate to high severity (≥30) on Oswestry Disability Index

**Exclusion criteria**

- Unable to have MRI
- Serious pathology
- Neurological deficit requiring urgent spinal surgery assessment
- Contralateral leg pain extending below the inferior gluteal margin
- Widespread pain throughout the body
- Prior use of biological agents within previous six months
- Previous lumbar spinal surgery
- Contra-indications to adalimumab injection
- Unable to give informed consent

**Randomisation**

Secure web-based randomisation was performed using a dynamic adaptive randomisation algorithm [20] to protect against subversion, while ensuring that the trial maintained good balance to the allocation ratio of 1:1 both within each stratification variable and across the trial. Participants were stratified by: (1) treatment centre and (2) presence of neurological signs (motor weakness or sensory loss).
**Interventions**

All participants were randomised to receive 80mg adalimumab sub-cutaneous injection followed two weeks later by 40mg in the posterior thigh, or an equivalent volume of 0.9% sodium chloride. Both groups received a concurrent course of physiotherapy over a period of 12 weeks [21,22].

**Internal pilot trial phase**

This aimed to assess the feasibility of the trial procedures, recruitment and retention rates, based on the first 50 participants recruited. The stopping criteria at the end of this internal pilot were: recruitment which failed to reach 80% of the planned recruitment rate target, drop outs exceeding 20%, or more than one centre failing to commence recruitment.

**Outcome measures**

The baseline questionnaire was administered by research physiotherapists. We planned to send postal questionnaires at six weeks, six and 12 months post-randomisation. The primary clinical outcome was back pain-related disability using the Oswestry Disability Index (ODI) [23] measured at 12 months, which has evidence of validity for sciatica as well as back pain. The primary economic outcome was Quality Adjusted Life Year (QALY) calculated from the EuroQol EQ-5D-5L [24].

**Condition specific outcomes**

- Oswestry Disability Index [23]
- Leg pain version of the Roland–Morris Disability Questionnaire [25,26]
- Sciatica Bothersomeness Index [27]
- Pain location using a pain manikin [28]
Generic outcomes

- EuroQol EQ-5D-5L [24]
- Global assessment of change since baseline

Psychological outcome

- Hospital Anxiety and Depression Scale [29]

Use of health care and social care services

- Resource Use Questionnaire [30,31]

Process Measures (potential predictors and mediators of outcome)

- STarT Back risk screening tool [32]
- Pain trajectory (based on a single question) [33]
- Pain self-efficacy questionnaire [34]
- Tampa Scale of Kinesiophobia [35]

Sample size

In order to detect an effect size of 0.4 with 90% power, 5% significance and 80% retention rate, 332 patients would have needed to be recruited.

Written qualitative comments

After the trial funding was withdrawn because of slow progress, the trial management team and all sites were asked to reflect on what worked and what did not work within the trial. Written comments were collated by the trial manager (AJ) and the chief investigator (NHW) and grouped into themes.
Results

Trial progress

Trial progress is compared with what was planned in Figure 2. The letter of notification of funding was received on 11\textsuperscript{th} August 2014. The trial documentation for the regulatory approval was in place in December 2014. Regulatory approval was obtained from the MHRA on 15\textsuperscript{th} April 2015 and the REC on 27\textsuperscript{th} May 2015. There were long delays in signing contracts with University 4 and NHS sites D and E, and contracts were never signed with University 5 and NHS site F (Table 1). There were delays obtaining the excess treatment costs for some sites in England. University 3 and NHS site C withdrew from the trial in February 2016. The trial initially opened to recruitment on 8\textsuperscript{th} December 2015 at NHS sites A and B, with sites D and E opening to recruitment on 11\textsuperscript{th} August 2016. The trial was closed early on 23\textsuperscript{rd} September 2016 due to poor recruitment.

Contracting

The main contract was between the funder (NIHR Health Technology Assessment) and University 1 which was one of the centres, and also acted as sponsor. Sub-contracts between University 1 and the participating centres and sites concerning roles and responsibilities and the available funding were a major issue. Initial sub-contract templates were drafted in November 2014, but could not proceed further until the main contract and finances were agreed with the funder in February 2015. Draft sub-contracts were sent to the relevant parties from University 1 contracts department on 31\textsuperscript{st} March 2015. The time taken to sign contracts is shown in Table 1.
There were protracted discussions about the nature and content of the sub-contracts, and division of responsibilities between the academic partners and the NHS sites. In the final adopted model, the sub-contracts were between the NHS sites and the sponsor, with universities providing academic support rather than taking on contractual responsibilities [36].

There were initial discussions about whether to have a tripartite sub-contract between University 1, 4 and NHS site D, but after further discussion it was agreed that University 1 would have separate sub-contracts. In addition, physiotherapy services were provided by two NHS sites and separate sub-contracts were needed for each. Two clinical rheumatology services were being merged during the trial set-up. The Clinical Trials Unit at University 4 had recently had a MHRA inspection in autumn 2015, and the learning from that recent inspection led to further discussions concerning sponsorship arrangements, delegated duties and the wording of the contract to clarify the role of the NHS sites, which resulted in further delay.

There remained several unresolved issues with University 5, who initially wanted a tripartite sub-contract between them, University 1 and NHS site F, but who later wanted to use the Brunswick research collaboration agreement instead [37]. In addition, MRI was to be undertaken by University 5, but because funding was allocated to the university rather than the NHS site, only 80% of the cost would be re-imburased, and who should pay for this underspend was left unresolved.

The funder also requested oversight of all the sub-contracts before they were signed. Delays with the sub-contracts led to delays with recruitment and retention of staff at the trial sites.
**Excess treatment costs**

In the UK the costs of a pharmacological treatment in a RCT are met by a participating pharmaceutical company, or by the participating NHS organisation, and not by the research funder. These excess treatment costs (ETC) amounted to more than £1,000 per participant in the intervention group. In Wales ETCs are managed centrally and were agreed by the Welsh Government for the two Welsh sites (A and F), whereas in England individual NHS sites are responsible. An ETC application was submitted to NHS site B in June 2014, and approved on 11\(^{th}\) March 2015. In NHS site D an initial application for ETC was declined due to insufficient funds. The co-investigators from University 4 led negotiations with both NHS site D and the local Clinical Commissioning Groups (CCGs). Both parties argued that they were not funded to support these ETCs, despite guidance on attributing the costs of health and social care research and development (AcoRD) [38]. Following negotiation it was agreed that the costs would be split between the local CCGs and the charitable funds from NHS site D. ETCs were approved for NHS site D on 19\(^{th}\) August 2015. Provisional ETCs were agreed for NHS site C, who were told that it would be finalised once research and development approval was given.

**Withdrawal of site**

Eight months after their initiation NHS site C reviewed the risk assessment of the trial. The locality has a high incidence of TB and there had recently been several difficult and complex cases treated locally, which had drawn the attention of the local press and community pressure groups [39,40]. Adalimumab is known to re-activate latent TB [19] and all patients should be evaluated for TB before commencing treatment. The principal investigator (PI) was worried about the risk of re-activating TB with the initial 80mg dose of adalimumab,
and decided to withdraw from the trial. Consequently University 3 also withdrew from the trial. This withdrawal led to a risk review for the other sites, who concluded that available data indicated an acceptable risk of infection in their populations, which was consistent with advice provided in the Patient Information Sheet.

**Research physiotherapist recruitment**

Delays in signing sub-contracts and setting up sites led to delays in recruiting the research physiotherapists at study sites. In NHS site A a physiotherapist was seconded from the NHS physiotherapy department, but was required to return to clinical duties because of staffing shortages. This led to delays in recruiting participants into the trial, and the loss of potential participants. The availability of research nurses and consultant rheumatologists was limited due to other clinical commitments, so co-ordination of biological agent counselling and investigations were difficult within the time available.

**Trial recruitment**

Recruitment data for the trial are presented in Figure 3 and reasons for withdrawal or exclusion in Table 2. NHS sites A and B recruited from December 2015 to September 2016. NHS sites D and E recruited from August to September 2016. Recruitment was lower than anticipated. Invitation letters were sent to 1,546 potential participants across sites A and B, 583 (38%) were interested in participating and underwent pre-screening by telephone. At pre-screening 210 (36%) did not have sciatica according to our criteria and 173 (30%) had symptoms for longer than six months, making them ineligible for the trial. Twenty five (4.3%) attended for screening at the first clinic assessment, 13
(52%) were eligible after the second clinical assessment and eight were randomised. The other five were eligible but could not be randomised due to study closure.

In NHS site A, 16 GP practices identified eligible patients presenting to the practice using database searches or opportunistic referral. Musculoskeletal clinics and physiotherapy departments also searched for eligible patients presenting to their clinics.

NHS site B mainly recruited from a secondary care back pain service rather than from primary care, and had a higher rate of exclusion because of longer duration of symptoms (19% of those excluded) than the other sites (NHS site A 4%, NHS sites D and E 5%). It was noted by the PI at this site that referrals of sciatica patients to the clinics had reduced between planning stages and the start of trial recruitment, due to a change in the referral pathway commissioned by the local CCG. Therefore, the planned recruitment pathway was changed to inviting GP practices to identify eligible patients by database search or opportunistic referral, independent of referral to specialist services. Database searches commenced at 12 practices in June 2016, 756 potential participants were identified by GP practices, 11 were invited to first clinical assessment screening, and five provided initial consent to participate before the trial was terminated.

NHS sites D and E had opened to recruitment on 11th August 2016, but the trial was closed on 26th September 2016. During this period there was a reasonable response rate of 14 out of 43 invitations to participate and nearly half of these, six out of 14, were from GPs handing out trial information packs during primary care consultations. This method of recruitment could have been more successful, but we were unable to test this properly before the trial closed. One patient who was eligible, after assessment by the research physiotherapist, was not able to participate because of trial closure.
Adverse events

No adverse events or adverse reactions were recorded for any of the eight participants.

Discussion

Summary of lessons learnt

This study has several important findings with major implications for developing evidence, within a UK setting, for challenging, expensive interventions with the potential for rare but significant side-effects. We found that treatment pathways for acute sciatica varied across research sites, and changed during the study period. This necessitated a flexible and heterogeneous approach to study recruitment, matching local treatment pathways. It was possible to introduce a novel treatment approach (biologic therapy) requiring specialist services (rheumatology), not normally a part of existing treatment pathways, within the context of a clinical trial. However, delivering this RCT was challenging, involving multiple professional groups across different healthcare organisations. In the future, additional feasibility studies, more efficient site set-up, improved and pilot tested recruitment methods and longer recruitment periods might be appropriate.

There were four main factors that led to delays and early trial closure: contracting issues; securing the payment of ETCs; site withdrawal due to concerns about re-activating TB in a highly prevalent area; and a complex trial recruitment process that did not always match local care pathways.

There were long delays agreeing and exchanging sub-contracts with participating centres and sites, and contractual discussions with one site were never concluded. Earlier
agreement between sponsor, university centres and NHS sites might have been facilitated by the use of model agreements such as the Brunswick research collaboration agreement [37]; site feasibility questionnaires; or research infrastructure that could facilitate the contracting process in multi-site research, such as the National Institute of Health Research Translational Research Partnership [41].

Negotiations for the ETCs were protracted in England, where responsibility for these costs had to be negotiated with different NHS organisations with competing cost pressures; new arrangements are needed [42].

One site withdrew from the RCT, before starting recruitment, because of a change in the PI’s perception of acceptable risk in the local population, fuelled by recent high-profile media cases. Further discussions between the Trial Management Group and the local PI around potential risks, related concerns and the degree of equipoise might have prevented site withdrawal.

During trial set up new national management guidance was published [6] as well as a new national back pain and radicular pain pathway [7]. In one site the local sciatica management pathway changed around the time that it opened to recruitment. This site initially only relied on referrals to its secondary care musculoskeletal service, but later involved the primary care research network, which was starting to identify participants just before trial closure. In the other open site there were operational issues identifying the research physiotherapist resource, and fitting the trial around the clinical commitments of participating clinicians.
The main method for identifying participants was retrospective GP record review, but this had a low rate of response with only a small proportion seen at the screening assessment. We had modelled the numbers of eligible participants for our recruitment projections on the previous Assessment and Treatment of Leg pain Associated with the Spine (ATLAS) cohort study, which identified patients in real-time as they were consulting, with retrospective record review only used as a back-up [43]. Although we identified large numbers of potential participants, only small numbers returned reply slips indicating a willingness to participate. It is not known why potentially eligible participants did not wish to participate. Informal feedback suggested that some patients might have been much improved by the time they were contacted about the trial, some might have found the trial procedures too burdensome, such as the complex two-stage recruitment process, whilst others might not have wished to participate in a RCT, especially in a clinical trial of an investigational medicinal product (CTIMP) involving a medication with significant potential adverse effects. Greater patient and public involvement could offer insights into how to explore this. Two of the clinical sites were going to recruit participants using the same methods as the ATLAS cohort, which have been successfully used in another RCT of a primary care delivered treatment for sciatica [44]. However, these two sites signed their contracts just prior to trial closure. Although potential participants had started to be identified, there was insufficient time to recruit them.

The current management of RCTs within the UK has emphasised recruitment efficiency and delivery of outcomes within short timelines [45]. This remains appropriate for treatments that fit within existing treatment pathways; when they do not, a new pathway must be developed specifically for the trial. In the current study we introduced medical screening
and biologic therapy administration, delivered through experienced secondary care rheumatology services. The heterogeneity of existing clinical pathways for sciatica (in primary and in secondary care) necessitated a multifaceted approach, with different solutions for different sites, requiring flexibility when pathways at single sites changed between the planning and execution of the trial.

**Comparison with previous literature**

The previous systematic review of biological agents for sciatica found a small number of RCTs and other studies with small numbers recruited [17]. Many of these studies also had poor rates of recruitment, both in the UK NHS [46] and elsewhere in Europe [47].

Slow or inadequate recruitment to publicly funded multicentre RCTs is still a common problem [48]. Systematic reviews of RCTs, that compared methods to increase trial recruitment, found that effective interventions included: telephone or text reminders two weeks after receiving their letter of invitation; the use of lay advocates who were already involved in the study; monetary incentives; and non-blinding of trial participants. The evaluation of recruitment strategies within RCTs was advocated [49,50]. Results of a systematic review concerning the recruitment activity of clinicians in RCTs include: the use of qualitative research to identify and overcome recruitment barriers, reduction of clinical workload associated with participation in RCTs, extra training and protected research time [51].

**Implications for future research**

We make a number of recommendations for future researchers (Box 1). A number of these are pertinent to all RCTs conducted in the UK. For example, we would recommend full
discussions between the sponsor’s contracting department and all university centres and NHS sites to obtain an early agreement about what the contracts need to include, and how the contracting process should be arranged, so that the university centres and the NHS sites have a clear understanding of their delegated roles and tasks. This may involve model contracts such as the Brunswick research collaboration agreements, which have been designed to be suitable for the majority of cases where two or more universities receive a joint research grant [40]. Early discussions about site requirements, perhaps using a site feasibility questionnaire, early dialogue with sites’ research and development departments and the early appointment of research staff in each site would facilitate trial set-up.

We also make recommendations pertinent to the circumstances of this particular RCT. The impact of research staff shortages, in this case a research physiotherapist at one site, could be avoided by having dedicated research staff. In addition, involvement of the research staff during the initial planning stage would have been useful for planning the recruitment strategy.

Further qualitative research is needed to identify reasons for low recruitment rates, using methods such as the QuinteT recruitment intervention, which uses a combination of standard and innovative qualitative research methods, with some simple quantification, to understand recruitment and identify sources of difficulty [52]. Possible reasons for poor recruitment include: concerns about the nature of the trial intervention and its side-effects; perceived burden of trial participation; natural history of recovery of severe sciatica; perceptions about the nature of sciatica itself, and whether the treatment under study is consistent with these. People who believe that their sciatica will resolve quickly (either spontaneously or with treatment) are unlikely to commit to a trial of medical intervention
with long follow up, particularly if they perceive that it would not provide (and might delay) definitive treatment. Such beliefs in the study population might not be well-founded in evidence, and pre-recruitment education might be necessary to help potential participants appreciate the possible benefits that might be achieved from novel interventions that are being investigated.

Patient recruitment from ‘real’ time GP consultations, may have reduced the delays associated with retrospective checks of GP consultations and from referrals to physiotherapy and secondary care settings. Unfortunately, because of delays in agreeing ETCs, and finalising contracts, there was insufficient time to recruit any participants using this method before trial closure.

Conclusions

A trial of biological therapy in patients with sciatica still needs to be performed, but would require a clearer contracting process, qualitative research to ensure that patients (and clinicians) would be willing to participate, and more efficient recruitment methods, with the least possible burden on patients.

List of abbreviations

AcoRD Attributing the costs of health and social care Research and Development
ATLAS Assessment and Treatment of Leg pain Associated with the Spine
CCGs Clinical Commissioning Groups
CTIMP Clinical Trial of an Investigational Medicinal Product
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETCs</td>
<td>Excess Treatment Costs</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>European Quality of Life-5 Dimensions</td>
</tr>
<tr>
<td>EudraCT</td>
<td>European Union Drug Regulating Authorities Clinical Trials</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>ISRCTN</td>
<td>International Standard Randomised Controlled Trial Number</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicine and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic Resonance Imaging</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>ODI</td>
<td>Oswestry Disability Index</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PIC</td>
<td>Patient Identification Centre</td>
</tr>
<tr>
<td>£</td>
<td>Pound Sterling</td>
</tr>
<tr>
<td>QALY</td>
<td>Quality-Adjusted Life Year</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Research and Development</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised Controlled Trial</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>SLR</td>
<td>Straight Leg Raise</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TNF-alpha</td>
<td>Tumour Necrosis Factor alpha</td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

**Declarations**
Ethics approval and consent to participate

The Wales Research Ethics Committee (REC) 3 granted approval on 27/05/2015 (15/WA/105), and clinical trial authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) was granted on 15/04/2015 (21996/0002/001-0001).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

Competing interests

NHW declares membership of the Health Technology Assessment (HTA) Primary Care, Community and Preventative Interventions Panel. DAH reports other grants from National Institute for Health Research (NIHR) during the conduct of the study and membership of the HTA Clinical Trials Board from 2010 to 2016, the HTA Funding Teleconference from 2015 to 2016 and the Pharmaceuticals Panel from 2008 to 2012. EW reports other grants from NIHR during the conduct of the study. NEF declares membership of the HTA Primary Care, Community and Preventative Interventions Panel. DAW reports grants from Pfizer Ltd and personal fees from Novartis Pharmaceuticals UK Ltd and Pfizer Ltd outside the submitted work. KK reports other grants from NIHR during the conduct of the study. JK reports personal fees from lectures (Pfizer Ltd, Merck & Co., Inc. and ORION Pharma GmbH), personal fees from a scientific advisory board (Axsome Therapeutics Inc.) and personal fees...
from stocks (ORION Pharma GmbH) outside the submitted work. SG reports grants from AbbVie Inc., Merck & Co., Inc., Pfizer Ltd, University Hospitals of Geneva, the Rheumasearch Foundation, Fondation de bienfaisance, Eugenio Litta and Centre de Recherches outside the submitted work.

**Funding**

This work was supported by the National Institute for Health Research’s Health Technology Assessment Programme, grant number 12/201/02. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS or the Department of Health.

**Authors’ contributions**

NHW was the chief investigator and grant holder, was responsible for study design, conduct and analysis, led the writing of this paper and had overall responsibility for the study. AJ was the trial manager overseeing day-to-day conduct. NG was the trial statistician. DAH was a co-investigator, contributed to study design. EW was trial health economist. NF was a co-investigator, contributed to methodology and study design. KK was a co-investigator, contributed to methodology and study design. DC was a co-investigator, contributed to methodology and study design. ZH gave input to study design, provided methodological oversight and support for the trial statistician. DM was a co-investigator, contributed to methodology and study design, provided physiotherapy expertise. VS was a co-investigator, contributed to methodology and study design, and provided physiotherapy expertise. DW was a co-investigator, responsible for study design, provided methodological oversight throughout the study. CW was a co-investigator. SG contributed to methodology and study
design. JK contributed to methodology and study design. JI gave input to study design. EH contributed to methodology and study design. All co-authors contributed to writing the paper and commented on drafts.

Acknowledgements

Particular thanks go to all the SCIATiC study participants who gave their time to take part in the study. The authors would also like to thank the NHS staff who screened patients and recruited participants in Betsi Cadwaladr University Health Board, Sherwood Forest NHS Foundation Trust, and Royal Wolverhampton NHS Trust. Also thanks to the physiotherapy department staff who provided support for the study, rheumatologists and their staff for supporting the study and providing access for researchers to the rheumatology clinics, rheumatology nurses for biologic counselling, recruiting participants and delivering the intervention, radiology department staff who provided support for the study, participating general medical practices for their contribution in identifying participants. Research and development departments of the various NHS organisations involved, clinical research networks for their contribution to patient recruitment and data collection. Clinical Trials Unit staff of the North Wales Organisation for Randomised Trials in Health. The independent members of the trial steering committee and the data monitoring and ethics committee. The Musculoskeletal Pain Clinical Studies Group of Arthritis Research UK for facilitating two workshops to develop the research idea and research proposal.

References


<table>
<thead>
<tr>
<th>University or NHS Site</th>
<th>Date sub-contract signed</th>
<th>Time to sign in days</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHS Site A</td>
<td>8\textsuperscript{th} April 2015</td>
<td>9</td>
</tr>
<tr>
<td>University 2</td>
<td>7\textsuperscript{th} July 2016</td>
<td>378</td>
</tr>
<tr>
<td>NHS Site B</td>
<td>20\textsuperscript{th} October 2015</td>
<td>197</td>
</tr>
<tr>
<td>University 3</td>
<td>24\textsuperscript{th} July 2015</td>
<td>115</td>
</tr>
<tr>
<td>NHS Site C</td>
<td>14\textsuperscript{th} August 2015</td>
<td>131</td>
</tr>
<tr>
<td>University 4</td>
<td>2\textsuperscript{nd} June 2016</td>
<td>427</td>
</tr>
<tr>
<td>NHS Site D</td>
<td>7\textsuperscript{th} July 2016</td>
<td>459</td>
</tr>
<tr>
<td>NHS Site E</td>
<td>7\textsuperscript{th} July 2016</td>
<td>459</td>
</tr>
<tr>
<td>University 5</td>
<td>Never signed</td>
<td>&gt;550</td>
</tr>
<tr>
<td>NHS Site F</td>
<td>Never signed</td>
<td>&gt;550</td>
</tr>
</tbody>
</table>
Table 2  Reasons for withdrawal and exclusion for patients in NHS sites A, B, D and E

<table>
<thead>
<tr>
<th>Reasons for withdrawal and exclusion from invitation to first clinical assessment</th>
<th>1520</th>
</tr>
</thead>
<tbody>
<tr>
<td>Did not confirm interest</td>
<td>963</td>
</tr>
<tr>
<td>No sciatica</td>
<td>210</td>
</tr>
<tr>
<td>Symptoms persisting for longer than six months</td>
<td>173</td>
</tr>
<tr>
<td>Widespread pain throughout body</td>
<td>25</td>
</tr>
<tr>
<td>No response or no longer interested</td>
<td>23</td>
</tr>
<tr>
<td>No leg pain</td>
<td>20</td>
</tr>
<tr>
<td>Complicated symptoms</td>
<td>18</td>
</tr>
<tr>
<td>Previous lumbar spinal surgery</td>
<td>16</td>
</tr>
<tr>
<td>Trial closed early to recruitment</td>
<td>14</td>
</tr>
<tr>
<td>Previous surgery</td>
<td>11</td>
</tr>
<tr>
<td>Symptoms resolved/improved</td>
<td>10</td>
</tr>
<tr>
<td>Pain in both legs</td>
<td>7</td>
</tr>
<tr>
<td>Contra-indications to MRI</td>
<td>6</td>
</tr>
<tr>
<td>Expressed interest but delay in tele-screening due to site staffing issues means no longer meet criteria for inclusion (e.g. no longer in pain or have recently breached the &gt;22week exclusion window since replying)</td>
<td>6</td>
</tr>
<tr>
<td>Serious spinal pathology</td>
<td>4</td>
</tr>
<tr>
<td>Unable to communicate in English or Welsh</td>
<td>3</td>
</tr>
<tr>
<td>Mental health problems</td>
<td>3</td>
</tr>
<tr>
<td>Current leg pain worse than or as bad as back pain</td>
<td>3</td>
</tr>
<tr>
<td>Previous episode of sciatica in the last six months</td>
<td>2</td>
</tr>
<tr>
<td>Incidental serious pathology identified by MRI</td>
<td>1</td>
</tr>
<tr>
<td>Previous use of biological agents targeting TNF-alpha</td>
<td>1</td>
</tr>
<tr>
<td>Contra-indications to adalimumab</td>
<td>1</td>
</tr>
<tr>
<td>Pregnant or breast-feeding</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reasons for withdrawal and exclusion from first clinical assessment to second clinical assessment</th>
<th>17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild symptoms – discharged to GP care</td>
<td>7</td>
</tr>
<tr>
<td>Study closure</td>
<td>5</td>
</tr>
<tr>
<td>Over time limit for second clinical assessment</td>
<td>1</td>
</tr>
<tr>
<td>TB screening failed</td>
<td>1</td>
</tr>
<tr>
<td>Participant revealed long term history of widespread pain at screening – particularly in shoulders</td>
<td>1</td>
</tr>
<tr>
<td>No positive neurological test</td>
<td>1</td>
</tr>
<tr>
<td>Reason</td>
<td>Count</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Patient did not attend appointment and could not be contacted</td>
<td>1</td>
</tr>
<tr>
<td>Reasons for withdrawal and exclusion from six week follow-up to six month follow-up</td>
<td>4</td>
</tr>
<tr>
<td>Study closure</td>
<td>4</td>
</tr>
</tbody>
</table>
Box 1  Ten lessons learnt for consideration in a future trial

<table>
<thead>
<tr>
<th>Contracts</th>
<th>1</th>
<th>Early agreement between sponsor, NHS sites and university centres about how the contracting process should be arranged with model research collaboration agreements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site set-up</td>
<td>2</td>
<td>Early discussions about site requirements using a site feasibility questionnaire</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Recruitment of a dedicated research physiotherapist (or other personnel) at each site</td>
</tr>
<tr>
<td>Treatment</td>
<td>4</td>
<td>Establish if the proposed treatment is acceptable to all principal investigators</td>
</tr>
<tr>
<td>acceptability</td>
<td>5</td>
<td>Determine if the proposed treatment is acceptable to sciatica patients, using further qualitative research</td>
</tr>
<tr>
<td>Recruitment</td>
<td>6</td>
<td>Simplify two-stage recruitment process</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>Use telephone or text reminders two weeks after patients receive letter of invitation</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Use of lay advocates already recruited into the study</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Recruitment during real-time GP consultations</td>
</tr>
<tr>
<td>Feasibility study</td>
<td>10</td>
<td>Feasibility study testing several key recruitment methods</td>
</tr>
</tbody>
</table>
Figure 1  Trial Flowchart

Failed primary care treatment or referred to local musculoskeletal service (>4/52, <6/12 duration, severe symptoms or recurrence), screened for eligibility criteria and trial information sent

Telephone contact by research physiotherapist to determine potential eligibility. If so appointment given for research physiotherapy clinic

Physiotherapy clinical assessment and screening

Severe symptoms, referral for MRI and 1st consent

MRI scan, TB screening, biological agent counselling, blood and urine tests

2nd clinical assessment, 2nd consent, baseline outcome measurement (n=332)

Remote Randomisation

Adalimumab injection 80mg then 40mg after 2 weeks (sub-cutaneous) (n=166)
Concurrent physiotherapy intervention

Placebo injection repeated after 2 weeks (n=166)
Concurrent physiotherapy intervention

Postal outcome measures at 6 weeks

Symptoms settled
Discharge back to GP care

Symptoms persist
Further treatment planned with MRI

Postal outcome measures at 6 months

Postal outcome measures at 12 months (n=266)

Semi-structured telephone interviews at 12 months (n=266)
## Figure 2  
**Trial timetable**

| Event                                                                 | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct |
|-----------------------------------------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Finalised protocol and trial documentation                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Ethics & NHS R&D Permission /MHRA Approvals                          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Expected                                                             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| MHRA                                                                 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| REC                                                                   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site A R&D                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site B R&D                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Sites D, E R&D                                                   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Staff training and site recruitment                                 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Contracts signed and completed                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Expected                                                             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site A                                                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site B                                                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site C                                                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Sites D, E                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Research physiotherapist recruitment                                 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Expected                                                             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site A                                                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site B                                                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Sites D, E                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Identification of potential participants                             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Expected                                                             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site A                                                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Site B                                                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NHS Sites D, E                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

*Key: Expected completion*
|                          |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  
| Telephone screening      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   
| Physio clinical assessment |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
Figure 3  Participant flow diagram for NHS sites A, B, D and E

Invited to participate by letter 1546  

Telephone pre-screening 583  

First screening assessment 25  

Second screening assessment Placebo 4, Adalimumab 4  

First injection Placebo 4, Adalimumab 4  

Second injection Placebo 4, Adalimumab 4  

Six week follow-up Placebo 4 Adalimumab 4  

Number at six month follow-up Placebo 2 Adalimumab 1  

Did not confirm interest 963  

Withdrawals and Exclusions 558  

Withdrawals and Exclusions 17  

Withdrawals and Exclusions 0  

Withdrawals 0  

Withdrawals 0  

Withdrawals Placebo 2 Adalimumab 3